Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158363 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL436024 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29547181 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29792115 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31681399 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29362301 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL21192401 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL5967470 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29401280 | 0.97 | MDM2 (0.58) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31614333 | 0.94 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3355931-B1 | PROTEIN CONJUGATES | NOVO NORDISK AS (DK) | 2024-06-26 | — | — | EP | disclosed |
| CN-106139158-B | Growth hormone with prolonged in vivo efficacy | 诺沃—诺迪斯克保健股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4303213-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Nihon Medi-Physics Co., Ltd. (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-117377759-A | Self-purified nucleic acid-encoded libraries | 约尔格·谢尔曼 | 2024-01-09 | — | — | CN | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230112418-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4116306-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Nihon Medi-Physics Co., Ltd (JP) | 2023-01-11 | — | — | EP | disclosed |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | ELI LILLY AND COMPANY | 2022-12-29 | — | — | US | disclosed |
| WO-2022186311-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | 日本メジフィジックス株式会社 | 2022-09-09 | — | — | WO | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| CN-103269720-A | Growth hormone conjugates | NOVO NORDISK HEALTHCARE AG | 2013-08-28 | — | — | CN | disclosed |
| CN-103002918-A | Growth hormone with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG | 2013-03-27 | — | — | CN | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| EP-2525834-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | Novo Nordisk Health Care AG (CH) | 2012-11-28 | — | — | EP | disclosed |
| CN-102612376-A | Growth hormone with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG | 2012-07-25 | — | — | CN | disclosed |
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-15 | — | — | US | disclosed |
| WO-2011089255-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172303-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | GHRHR, GHITM, SHBG | MDM2 260/4885MDM4 3463/4885TP53 1051/4885 |
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | MDM2 938/4885MDM4 1827/4885TP53 130/4885 |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | MDM2 179/4885MDM4 1988/4885TP53 403/4885 |
| US-20230112418-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | ALB, TFRC, FABP2 | MDM2 717/4885MDM4 1173/4885TP53 209/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | MDM2 180/4885MDM4 1876/4885TP53 796/4885 |
| US-20240174622-A1 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | PSMA2, PSMA1, PSMA3 | MDM2 191/4885MDM4 386/4885TP53 1163/4885 |
| US-20220411461-A1 | METHODS OF MAKING INCRETIN ANALOGS | IAPP, GLP1R, GIPR | MDM2 2077/4885MDM4 4057/4885TP53 4065/4885 |
| US-20110223151-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | F13B, F13A1, F2 | MDM2 3834/4885MDM4 4759/4885TP53 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.